The targeted protein degradation enabling technologies market, featuring a healthy pipeline of novel therapeutics, is anticipated to be worth over USD 3.3 billion by 2030, predicts Roots Analysis
Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.
Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.
To order this 330+ page report, which features 115+ figures and 180+ tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Key Market Insights
Presently, more than 150 targeted protein degradation-based therapeutics are currently under development
Around 75% of the aforementioned candidates are in the preclinical and discovery stages, followed by those that are being evaluated in clinical trials (25%). The these degrader molecules are PROTAC (26), followed by DUB inhibitors (15%), protein homeostatic modulators (14%) and SERDs/SARDs (13%).
Over 40 targeted protein degradation enabling technologies are presently available / under development
Of these, the PROTAC® platform is presently considered the most popular, with 15 product candidates, developed using the same technology, under investigation. On the other hand, there are presently 10 technologies that are designed to design / develop DUB inhibitors.
Around 80 companies claim to be engaged in the development of targeted protein degradation-based therapeutics
Post 2010, there has been a notable surge in the number of companies developing targeted protein degraders. Majority of the firms engaged in this field (57%) are based in North America, followed by Europe (27%) and the Asia Pacific (16%).
Over 80 registered clinical trials are presently assessing targeted protein degradation-based therapeutics, worldwide
It is worth mentioning that most of the clinical research in this direction is being conducted in Europe (60%), followed by North America and the Asia Pacific. However, more than 40% of the total number of patients enrolled in such trials are in North America.
Over 770 grants have been awarded to support research on targeted protein degradation-based therapeutics, since 2016
An estimate total of USD 345 million in grants have been awarded to various organizations working in this domain, during the period between January 2016 to December 2020. Almost 40% of the total number of grants were provided by the National Cancer Institute.
More than 14,500 patents have been filed / granted related to targeted protein degradation enabling technologies, since 2018
Around 50% of these intellectual property documents were filed / granted in the US; other key regions with significant intellectual capital include Australia, China, Japan, Canada and Korea. Leading non industry players (in terms of the size of intellectual property portfolio) include the University of California, Massachusetts Institute of Technology, Broad Institute, Harvard College and Dana Farber Cancer Institute.
Partnership activity within this domain has grown significantly between 2014 and 2021
The maximum number of partnerships for targeted protein degradation-based therapeutics were signed in 2018. R&D agreements (25%) and research agreements (23%) emerged as the most popular types of partnership models adopted so far, by stakeholders in this industry.
Over USD 5 billion has been invested by both private and public investors, since 2014
Companies involved in the development of targeted protein degradation-based therapeutics have raised around USD 2.3 billion through venture capital financing, which represents 43% of the total capital raised in the given time period. Overall, more than 180 investors have actively financed projects / initiatives in this domain.
Presently, the market is driven by revenues from therapy development enabling technologies; it is anticipated to grow at a CAGR of around 27%, till 2030
Over 50% of the technology licensing-related opportunity is associated with platforms intended for drugs targeting oncological disorders; this trend is unlikely to change in the foreseen future. North America is expected to capture over 55% of the market share by 2030.
To request a sample of this report, please visit https://www.rootsanalysis.com/reports/289/request-sample.html
Key Questions Answered
Who are the leading industry and non-industry players in this market?
What are the key therapeutic areas for which targeted protein degraders are being / have been developed?
Which geographies are more active in conducting clinical trials on targeted protein degraders?
What kind of partnership models are commonly adopted by industry stakeholders?
Which are the leading administering institute centers supporting research in this domain?
What is the trend of capital investments in the targeted protein degradation market?
How has the intellectual property landscape in this market evolved over the years?
How is the current and future market opportunity likely to be distributed across key market segments?
The USD 3.3 billion (by 2030) financial opportunity within the targeted protein degradation enabling technologies market has been analyzed across the following segments:
Type of Payment
Types of Protein Degraders
SARDs / SERDs
Specific BET and DUB Inhibitors
Route of Administration
Key Geographical Regions
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), brief descriptions of its proprietary drug(s) and an informed future outlook.
For additional details, please visit
or email email@example.com
You may also be interested in the following titles:
1. Immunocytokines Market, 2021–2030
2. Non-Viral Drug Delivery Systems Market, 2021-2030
3. TCR-based Therapies Market, 2021-2030
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
+1 (415) 800 3415
+44 (122) 391 1091
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The targeted protein degradation enabling technologies market, featuring a healthy pipeline of novel therapeutics, is anticipated to be worth over USD 3.3 billion by 2030, predicts Roots Analysis here
News-ID: 2327904 • Views: 432
More Releases from Roots Analysis
The Agricultural Biologicals Market Size Worth over USD 40 Billion in 2035 | Roo …
Global Agricultural Biologicals Market Overview The agricultural biologicals market is a rapidly growing and dynamic industry that is poised to grow at a CAGR of 9.98% in the forecast period 2023-2035. The growth in the agricultural biologicals market size over the next decade is likely to be the result of a rise in the demand for organic food coupled with the growing focus on sustainable agriculture. Agricultural biologics include a vast
The Lab Automation Market is anticipated to grow at a CAGR of around 15% by 2035 …
Owing to the advanced features and cost-saving potential of automation, stakeholders in the healthcare industry are adopting lab automation systems in order to get precise results and reduce deviations occurring due to manual handling Roots Analysis has announced the addition of "Lab Automation Market, 2023-2035" report to its list of offerings. The diverse applications of lab automation systems, including advanced data management, high reproducibility and increased productivity in the biotechnology
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growi …
Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development London Roots Analysis has announced the addition of "Gene Therapy Market" report to its list of offerings. Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type
The companion diagnostics development services market, is anticipated to grow at …
Roots Analysis has announced the addition of "Companion Diagnostics Development Services Market (2nd Edition), 2022-2035" report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of
More Releases for PROTAC
New Technology of PROTACs
Most of the drugs currently in clinical use are based on small molecules and use the "occupancy-driven" mode of action to inhibit the function of proteins and play a role in the treatment of diseases. Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its ability to induce the degradation of therapeutic target proteins, providing a new idea for the
Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Developmen …
Profacgen, an experienced provider in biological research and drug discovery, provides various ubiquitin services to help customers accelerate research progress and obtain better results. Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of proteins. Therefore, the study of protein ubiquitination plays an important role in cell biology and drug discovery. With the comprehensive advanced platform, Profacgen
PROteolysis Targeting Chimera (PROTAC) Market Key-Players and Forecast Research …
The Global PROteolysis Targeting Chimera (PROTAC) Market Report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report. "Due to Financial Year
PROteolysis Targeting Chimera (PROTAC) Market to Witness Huge Growth by Key Play …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the PROteolysis Targeting Chimera (PROTAC) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The PROteolysis Targeting Chimera (PROTAC) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the PROteolysis Targeting Chimera (PROTAC)
Targeted Protein Degradation Market, 2021-2030
Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare London Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings. Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the
The targeted protein degradation market is projected to grow at an annualized ra …
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to